Long-acting injectable (LAI) cabotegravir/rilpivirine (CAB/RPV) provides an effective treatment option for people with HIV (PWH). Studies suggest that PWH on LAI CAB/RPV may experience isolated episodes of transient viremia (HIV RNA > 20 copies/mL) defined as virologic blips (VB). The risk factors for VB in PWH receiving LAI CAB/RPV are limited. We aimed to describe a cohort of PWH on LAI CAB/RPV and evaluate risk factors and time to VB following LAI CAB/RPV initiation. We obtained DC Cohort data from PWH who initiated LAI CAB/RPV prior to July 2023 and used Kaplan–Meier curves and Cox proportional hazards models to evaluate the association between participant demographics, HIV clinical factors, and time to VB. Among 98 PWH who initiated LAI CAB/RPV, 9 (9.2%) experienced at least one VB (median HIV RNA = 50 copies/mL; ranges 30–12,000 copies/mL) during a median follow-up period of five months (IQR: 2–10). The median CD4 count among PWH was 754 cells/µL (IQR: 598, 980) at the time of LAI CAB/RPV initiation. Having a high CD4 (≥ 500 cells/μL) at LAI CAB/RPV initiation was significantly associated with a lower hazard for VB when compared to baseline CD4 < 200 cells/µL [hazard ratios (HR): 0.15 [95% confidence intervals (CI): 0.03, 0.77]; aHR: 0.07 (95% CI: 0.01, 0.50); log-rank p = .026]. No other characteristics were significantly associated with time to VB, and no participants experienced virologic failure. Considerations for baseline CD4 may be important when initiating a patient on LAI CAB/RPV, and future studies will help evaluate the VB occurrence and associated factors among PWH.
Get full access to this article
View all access options for this article.
References
1.
DieffenbachCW, FauciAS. Thirty years of HIV and AIDS: Future challenges and opportunities. Ann Intern Med, 2011; 154(11):766–771; doi: 10.7326/0003-4819-154-11-201106070-00345
Centers for Disease Control and Prevention. Diagnoses, Deaths, and Prevalence of HIV in the United States and 6 Territories and Freely Associated States, 2022. HIV Surveillance Report. March 14, 2023. Available from: https://www.cdc.gov/hiv-data/nhss/hiv-diagnoses-deaths-prevalence.html
4.
GonzalezA, BarinasJ, O’CleirighC. Substance use: Impact on adherence and HIV medical treatment. Curr HIV/AIDS Rep, 2011; 8(4):223–234; doi: 10.1007/s11904-011-0093-5
5.
KatzIT, RyuAE, OnuegbuAG, et al.Impact of HIV-related stigma on treatment adherence: Systematic review and meta-synthesis. J Int AIDS Soc, 2013; 16(3)(Suppl 2):18640; doi: 10.7448/IAS.16.3.18640
6.
BenningL, MantsiosA, KerriganD, et al.Examining adherence barriers among women with HIV to tailor outreach for long-acting injectable antiretroviral therapy. BMC Womens Health, 2020; 20(1):152; doi: 10.1186/s12905-020-01011-8
7.
ChristopoulosKA, ColasantiJ, JohnsonMO, et al.Are patients and their providers talking about long-acting injectable antiretroviral therapy? penetration into clinical encounters at three U.S. Care Sites. Open Forum Infect Dis, 2022; 9(7):ofac293; doi: 10.1093/ofid/ofac293
8.
Gede Arya Bagus Arisudhana, Muchlis Achsan Udji Sofro, Untung Sujianto. Antiretroviral Side Effects on Adherence in People Living with HIV/AIDS. Journal of Nursing, 2018; 8(2):79–85.
9.
AmmassariA, MurriR, PezzottiP, et al.;AdICONA Study Group. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV Infection. J Acquir Immune Defic Syndr, 2001; 28(5):445.
10.
PintoRM, HallE, TomlinR. Injectable long-acting Cabotegravir–Rilpivirine therapy for people living with HIV/AIDS: Addressing implementation barriers from the start. J Assoc Nurses AIDS Care, 2023; 34(2):216–220; doi: 10.1097/JNC.0000000000000386
11.
RizzardiniG, OvertonET, OrkinC, et al.Long-acting injectable Cabotegravir + Rilpivirine for HIV maintenance therapy: Week 48 pooled analysis of Phase 3 ATLAS and FLAIR Trials. J Acquir Immune Defic Syndr, 2020; 85(4):498–506; doi: 10.1097/QAI.0000000000002466
12.
Cabenuva (cabotegravir extended-release injectable suspension; rilpivirine extended-release injectable suspension), co-packaged for intramuscular use [package insert]. Food and Drug Administration. 2023. Accessed January 27, 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212888s000lbl.pdf
SaxPE, ThompsonMA, SaagMS, IAS-USA Treatment Guidelines Panel. Updated treatment recommendation on use of cabotegravir and rilpivirine for people with HIV from the IAS-USA guidelines panel. JAMA, 2024; 331(12):1060–1061; doi: 10.1001/jama.2024.2985
15.
GandhiM, HickeyM, ImbertE, et al.Demonstration project of long-acting antiretroviral therapy in a diverse population of people with HIV. Ann Intern Med, 2023; 176(7):969–974; doi: 10.7326/M23-0788
16.
ChristopoulosKA, GrochowskiJ, Mayorga-MunozF, et al.First demonstration project of long-acting injectable antiretroviral therapy for persons with and without detectable Human Immunodeficiency Virus (HIV) Viremia in an Urban HIV Clinic. Clin Infect Dis, 2023; 76(3):e645–e651; doi: 10.1093/cid/ciac631
17.
BrockJB, HerringtonP, HickmanM, HickmanA. Long-acting injectable cabotegravir/rilpivirine effective in a small patient cohort with virologic failure on oral antiretroviral therapy. Clin Infect Dis, 2024; 78(1):122–124; doi: 10.1093/cid/ciad511
18.
HsuRK, SensionM, FuscoJS, et al.1028. real-world use of long-acting cabotegravir + rilpivirine in people with HIV with detectable viral loads at initiation: Findings from the OPERA® Cohort. Open Forum Infect Dis, 2023; 10(Suppl 2); doi: 10.1093/ofid/ofad500.059
19.
ChenW, GandhiM, SaxPE, et al.Projected benefits of long-acting antiretroviral therapy in nonsuppressed people with human immunodeficiency virus experiencing adherence barriers. Open Forum Infect Dis, 2023; 10(8):ofad390; doi: 10.1093/ofid/ofad390
20.
GandhiRT, BedimoR, HoyJF, et al.Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 Recommendations of the international antiviral society–USA Panel. JAMA, 2023; 329(1):63–84; doi: 10.1001/jama.2022.22246
RakhmaninaN, RichardsK, Adeline KoayWL. Transient viremia in young adults with HIV after the switch to long-acting cabotegravir and rilpivirine: Considerations for dosing schedule and monitoring. J Acquir Immune Defic Syndr, 2023; 92(3):e14–e17; doi: 10.1097/QAI.0000000000003142
CutrellAG, SchapiroJM, PernoCF, et al.Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: A multivariable analysis. AIDS, 2021; 35(9):1333–1342; doi: 10.1097/QAD.0000000000002883
28.
OrkinC, SchapiroJM, PernoCF, et al.Expanded multivariable models to assist patient selection for long-acting cabotegravir + rilpivirine treatment: Clinical utility of a combination of patient, drug concentration, and viral factors associated with virologic failure. Clin Infect Dis, 2023; 77(10):1423–1431; doi: 10.1093/cid/ciad370
29.
GreenbergAE, HaysH, CastelAD, et al.;DC Cohort Executive Committee. Development of a large urban longitudinal HIV clinical cohort using a web-based platform to merge electronically and manually abstracted data from disparate medical record systems: Technical challenges and innovative solutions. J Am Med Inform Assoc, 2016; 23(3):635–643; doi: 10.1093/jamia/ocv176
GreenlandS, MansourniaMA, AltmanDG. Sparse data bias: A problem hiding in plain sight. BMJ, 2016; 352:i1981; doi: 10.1136/bmj.i1981
32.
World Health Organization. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. 2nd ed. World Health Organization; 2016. https://iris.who.int/handle/10665/208825
33.
ThoueilleP, SaldanhaSA, SchallerF, et al.;Swiss HIV Cohort Study. Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: A multicenter prospective observational study in Switzerland. Lancet Reg Health Eur, 2024; 36:100793; doi: 10.1016/j.lanepe.2023.100793
34.
WilliamsT, AndersonL, UnternaherJ, et al.Adolescents and young adults with HIV using long-acting injectable cabotegravir/rilpivirine as a standard of care: Outcomes of the observational cohort at 26 months. In: AIDS 2024 - Conference Abstract. 2024. https://programme.aids2024.org/Abstract/Abstract/?abstractid=2788
35.
HillL, KenneyS, PatelN, et al.Predictors of post-switch Viremia in people with HIV on injectable cabotegravir/Rilpivirine. J Acquir Immune Defic Syndr, 2024; 95(1):90–96; doi: 10.1097/QAI.0000000000003320
36.
GutiérrezF, Fernández-GonzálezM, LedesmaC, et al.Virological history predicts non-sustained viral suppression with long-acting cabotegravir and rilpivirine therapy, independent of pharmacokinetic parameters. Clin Infect Dis, 2024; ciae475; doi: 10.1093/cid/ciae475
37.
OpokuJ, DoshiRK, CastelAD, et al.Comparison of clinical outcomes of persons living with HIV by enrollment status in Washington, DC: Evaluation of a large longitudinal HIV cohort study. JMIR Public Health Surveill, 2020; 6(2):e16061; doi: 10.2196/16061
38.
van WelzenBJ, Van LelyveldSFL, Ter BeestG, et al.Virological failure after switch to long-acting cabotegravir and rilpivirine injectable therapy: An in-depth analysis. Clin Infect Dis, 2024; 79(1):ciae016–ciae195; doi: 10.1093/cid/ciae016
39.
OomenPGA, DijkstraS, HofstraLM, et al.Integrated analysis of viral blips, residual viremia, and associated factors in people with HIV: Results from a retrospective cohort study. J Med Virol, 2023; 95(10):e29178; doi: 10.1002/jmv.29178
40.
ZhangT, DingH, AnM, et al.Factors associated with high-risk low-level viremia leading to virologic failure: 16-year retrospective study of a Chinese antiretroviral therapy cohort. BMC Infect Dis, 2020; 20(1):147; doi: 10.1186/s12879-020-4837-y
41.
FarmerA, WangX, GanesanA, et al.Factors associated with HIV viral load “blips” and the relationship between self-reported adherence and efavirenz blood levels on blip occurrence: A case–control study. AIDS Res Ther, 2016; 13(1):16; doi: 10.1186/s12981-016-0100-4
42.
DijkstraS, HofstraLM, MudrikovaT, et al.Lower incidence of HIV-1 blips observed during integrase inhibitor–based combination antiretroviral therapy. J Acquir Immune Defic Syndr, 2022; 89(5):575–582; doi: 10.1097/QAI.0000000000002898
43.
ElvstamO, MalmbornK, ElénS, et al.Virologic failure following low-level viremia and viral blips during antiretroviral therapy: Results from a European multicenter cohort. Clin Infect Dis, 2023; 76(1):25–31; doi: 10.1093/cid/ciac762
44.
BettonteS, BertonM, StaderF, BattegayM, MarzoliniC. Effect of obesity on the exposure of long-acting cabotegravir and rilpivirine: A Modelling Study. Clin Infect Dis Off Publ Infect Dis Soc Am, 2024; 79(2):ciae060–ciae486; doi: 10.1093/cid/ciae060
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
